Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 2/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.40 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.40 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15070694 | 1.00 | CASR (0.47) | CASRPLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL9496434 | 1.00 | CASR (0.47) | CASRPLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL9495170 | 1.00 | CASR (0.47) | CASRPLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL16104620 | 1.00 | CASR (0.47) | CASRPLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL9159602 | 1.00 | CASR (0.47) | CASRPLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL30515121 | 1.00 | CASR (0.47) | CASRPLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL10412255 | 0.98 | CASR (0.46) | CASRPLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL17445655 | 0.94 | CASR (0.43) | CASRPLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL9851905 | 0.92 | CASR (0.43) | CASRPLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL25289434 | 0.92 | USP2 (0.50) | CASRPLA2G2APLA2G10PLA2G1BPLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200016264-A1 | NUCLEIC ACID OF FORMULA (I): GlXmGn, OR (II): ClXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT | CUREVAC AG (DE) | 2020-01-16 | — | — | US | disclosed |
| US-10441653-B2 | Nucleic acid comprising GlXmGn as an immune-stimulating agent/adjuvant | CUREVAC AG (DE) | 2019-10-15 | — | — | US | disclosed |
| EP-2650368-A1 | Nucleic acid of formula (I): GlXmGn, or (II): ClXmCn, in particular as an immune-stimulating agent/adjuvant | CureVac GmbH (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-20130121988-A1 | Nucleic Acid of Formula (I): GlXmGn, or (II): ClXmCn, in Particular as an Immune-Stimulating Agent/Adjuvant | CUREVAC GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130121988-A1 | Nucleic Acid of Formula (I): GlXmGn, or (II): ClXmCn, in Particular as an Immune-Stimulating Agent/Adjuvant | CUREVAC GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20090324584-A1 | Nucleic Acid of Formula (I): GIXmGn, or (II): CIXmCn, in Particular as an Immune-Stimulating Agent/Adjuvant | CUREVAC GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20090324584-A1 | Nucleic Acid of Formula (I): GIXmGn, or (II): CIXmCn, in Particular as an Immune-Stimulating Agent/Adjuvant | CUREVAC GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20070280929-A1 | ADJUVANT IN THE FORM OF A LIPID-MODIFIED NUCLEIC ACID | CUREVAC GMBH (DE) | 2007-12-06 | — | — | US | disclosed |
| US-20070280929-A1 | ADJUVANT IN THE FORM OF A LIPID-MODIFIED NUCLEIC ACID | CUREVAC GMBH (DE) | 2007-12-06 | — | — | US | disclosed |
| WO-2007095976-A2 | ADJUVANT IN THE FORM OF A LIPID-MODIFIED NUCLEIC ACID | CUREVAC GMBH (DE) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324584-A1 | Nucleic Acid of Formula (I): GIXmGn, or (II): CIXmCn, in Particular as an Immune-Stimulating Agent/Adjuvant | TLR9, MYD88, TLR3 | CASR 435/4885PLA2G2A 131/4885PLA2G10 80/4885 |
| US-20070280929-A1 | ADJUVANT IN THE FORM OF A LIPID-MODIFIED NUCLEIC ACID | TLR5, TLR9, TLR7 | CASR 3765/4885PLA2G2A 84/4885PLA2G10 58/4885 |
| US-20130121988-A1 | Nucleic Acid of Formula (I): GlXmGn, or (II): ClXmCn, in Particular as an Immune-Stimulating Agent/Adjuvant | TLR9, POLN, TLR5 | CASR 1760/4885PLA2G2A 151/4885PLA2G10 141/4885 |
| US-20200016264-A1 | NUCLEIC ACID OF FORMULA (I): GlXmGn, OR (II): ClXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT | TLR9, TLR3, TLR5 | CASR 874/4885PLA2G2A 113/4885PLA2G10 89/4885 |
| US-10441653-B2 | Nucleic acid comprising GlXmGn as an immune-stimulating agent/adjuvant | TLR9, TLR7, GMNN | CASR 1752/4885PLA2G2A 88/4885PLA2G10 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.